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Abstract
The global rise in obesity and gestational weight gain, along with recent trials demonstrating improved pregnancy
and neonatal outcomes associated with the treatment of mild hyperglycaemia, have resulted in a clinical challenge
to deliver cost effective healthcare to manage the epidemic of Gestational Diabetes Mellitus (GDM). Whilst clinicians
now have clear criteria by which to diagnose GDM, and the glycaemic targets to achieve, less clear are the
pathways to achieve these outcomes in a cost effective manner. The value of using allied health providers such as
dieticians compared to less trained patient educators, the effectiveness of individualised versus group dietician
counselling, the role of antenatal investigations such as CTG and ultrasound, the degree of monitoring of maternal
blood sugar level, the type of medications to complement dietary therapy, along with policies on delivery and
postnatal care, all need to be refined through studies or audits. Having identified the problem and established
diagnostic and treatment targets, the next challenge is to provide evidence-based, cost-effective care.
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Mini-review
The rising tide of global obesity and diabetes has seen Gestational
Diabetes Mellitus (GDM) assume increasing public health
significance. More than a third of pregnant women in the developed
world present for care with a body mass index consistent with
overweight or obesity [1-3]. Many pregnant women also have
gestational weight gain in excess of Institute of Medicine
recommendations [1-4]. These changes have seen global rates of GDM
soar.
Until recently, the diagnosis and management of GDM was based
upon expert opinion. Following publication of the Hypoglycaemia and
Adverse Pregnancy Outcomes (HAPO) trial in 2008, it became
possible to conduct trials and evaluate clinical service against
outcomes that could be directly linked to pregnancy hyperglycaemia
[5].
The HAPO trial of 23,316 women documented clear associations
between hyperglycaemia at 24-28 weeks gestation and adverse
maternal and neonatal outcomes [5]. Results revealed a continuum
across which glycaemia levels were associated with adverse outcomes.
In the absence of a categorical cut off, the International Association of
Diabetes and Pregnancy Study Groups (IADPSG) panel recommended
the diagnostic criteria should be blood sugar levels that were associated
with an odds ratio of 1.75 for producing adverse outcomes compared
to mean glucose levels [6].
Whilst no trial has specifically utilised these cut off points,
randomised trials of intervention in women with mild hyperglycaemia
in pregnancy have documented a broad range of benefits including
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reductions in birth weight >90th centile, caesarean section, neonatal
hypoglycaemia and cord C-peptide >90th centile [7-9].
Following an evaluation of data from available trials, authorities
recommended new criteria to diagnose GDM (Table 1). These targets
are based upon blood sugar levels following a 75 g Oral Glucose
Tolerance Test (OGTT) performed between 24-28 weeks gestation.
Treatment targets have also been refined in line with results from these
published trials and expert opinion (Table 2)[7-11].
New diagnostic criteria for Gestational Diabetes*
Fasting Blood Sugar Level (BSL): >5.0 mmol/l
1-hour BSL: >10mmol/l
2-hour BSL: >8.4mmol/l
*Cut

off points following a 75 gram oral glucose tolerance test performed
between 24-28 weeks pregnancy
*One

or more must be abnormal for a diagnosis of GDM

Table 1: Diagnosis of Gestational Diabetes Mellitus
New treatment targets for Gestational Diabetes
Fasting Blood Sugar Level (BSL): <5.1 mmol/l
1-hour BSL: <7.5 mmol/l
2-hour BSL: <6.8 mmol/l

Table 2: Treatment targets for Gestational Diabetes Mellitus
Unfortunately, achieving consensus in the diagnosis and treatment
targets for GDM is only the starting point. Clinicians now face the
challenge to deliver care for women whose pregnancy is complicated
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with GDM so that therapeutic outcomes are achieved in a cost
effective way.
Since the aim of care is to achieve glycaemic control, dietary
interventions are key. However, dietary interventions range in price.
The cheapest models provide women with a written pamphlet. The
next step up would be models of care where a patient educator
provides patients with written information and dietary counselling,
through to group sessions with a qualified dietician, to repeated
individualised sessions with a dietician at the extreme price range. The
cost of these interventions ranges from US$1 to US$300 per patient
[2]. A direct comparison of the relative efficacy of these differing
approaches, with other factors controlled, has not occurred.
The next question is drug therapy. Fortunately, nearly 70% of
patients with GDM can be managed with dietary intervention alone.
However, the remaining patients require medication. Until recently
this was exclusively administered as insulin, but in recent years
Metformin has been substituted for insulin with comparable outcomes
[12,13]. However, patients with high blood sugar levels usually benefit
from insulin or combined therapy [13].
The type of monitoring required in pregnancy complicated by
GDM is also unclear. Fetal cardiotocography and ultrasound have
been utilised to manage pregnancy but their ‘value add’ in
management is unclear [7-9].
Likewise, the ideal time to deliver patients whose pregnancy is
complicated by GDM is subjected to debate. When fetal compromise
is present, timing of delivery is dependent upon fetal factors. However,
it is less clear whether a pregnancy complicated by GDM but
subsequently managed with good glycaemic control and normal fetal
growth should warrant induction or be left to await natural labour.
Postnatal management is also diverse. Some centers monitor babies
for 48 hours with serial blood sugar levels whilst others are happy for
expedited discharge.
Strangely the one intervention that has a substantiated evidence
base, a postnatal OGTT performed between 6-12 weeks postpartum to
detect women with type 2 diabetes, seems to slip through the practice
net. Studies show up to 16% and 6% of women with GDM will have
ongoing glucose intolerance or type 2 diabetes respectively by three
months postpartum. Therefore, this patient population represents a
cohort where early diagnosis and intervention could achieve benefits
in terms of long term chronic disease morbidity [14]. Yet follow up is
inconsistent [15].
Clinicians need to streamline the management of GDM to ensure
interventions are effective and efficient. Streamlined pathways are
required to deliver dietary advice, monitor glycaemia and monitor
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fetal wellbeing without undue intervention secondary to antenatal tests
and labour induction.
These are the next wave of challenges for clinicians.

References
1.
2.
3.

4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.

Quinlivan JA (2014) Cost effective evidence-based interventions to
manage obesity in pregnancy. World J Obstet Gynecol 3: 67-70.
Quinlivan JA, Lam LT, Fisher J (2011) A randomised trial of a four-step
multidisciplinary approach to the antenatal care of obese pregnant
women. Aust N Z J Obstet Gynaecol 51: 141-146.
Quinlivan JA, Julania S, Lam L (2011) Antenatal dietary interventions in
obese pregnant women to restrict gestational weight gain to institute of
medicine recommendations: a meta-analysis. Obstetrics and Gynecology
118: 1395-1401.
Institute of Medicine (2009) Weight gain during pregnancy: Reexamining the guidelines. Report Brief.
HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer
AR, Trimble ER, et al. (2008) Hyperglycemia and adverse pregnancy
outcomes. N Engl J Med 358: 1991-2002.
IADPSG Consensus Panel (2010) International association of diabetes
and pregnancy study groups recommendations on the diagnosis and
classification of hyperglycaemia in pregnancy. Diabetes Care 33: 676-682.
Hoffman L, Nolan C, Wilson JD, Oats JJ, Simmons D (1998) Gestational
diabetes mellitus--management guidelines. The Australasian Diabetes in
Pregnancy Society. Med J Aust 169: 93-97.
Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, et al. (2005)
Effect of treatment of gestational diabetes mellitus on pregnancy
outcomes. N Engl J Med 352: 2477-2486.
Landon M, Spong C, Thom E, Carpenter M, Ramin S, et al. (2009) A
multicentre randomised trial of treatment for mild gestational diabetes.
The New England Journal of Medicine 361: 1339-1348.
Riskin-Mashiah S, Damti A, Younes G, Auslander R (2011) Normal
fasting plasma glucose levels during pregnancy: a hospital-based study.
Journal of Perinatal Medicine 39: 209-211.
Hernandez TL, Friedman JE, Van Pelt RE, Barbour LA (2011) Patterns of
glycemia in normal pregnancy: should the current therapeutic targets be
challenged? Diabetes Care 34: 1660-1668.
Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial
Investigators (2008) Metformin versus insulin for the treatment of
gestational diabetes. N Engl J Med 358: 2003-2015.
Gui J, Liu Q, Feng L (2013) Metformin vs insulin in the management of
gestational diabetes: a meta-analysis. PLoS One 8: e64585.
Quinlivan JA, Lam D (2013) Cholesterol abnormalities are common in
women with prior gestational diabetes. Journal of Diabetes and
Metabolism 4: 255.
Chittleborough CR, Baldock KL, Taylor AW, Hague WM, Willson T, et
al. (2010) Long-term follow-up of women with gestational diabetes
mellitus: the South Australia gestational Diabetes Mellitus recall register.
Aust N Z J Obstet Gynaecol 50: 127-131.

Volume 3 • Issue 4 • 1000144

